According to a study sponsored by Danish pharmaceutical company Novo Nordisk, it cost $218 billion to treat type 1 and 2 diabetes in the United States in 2007. Of that amount, the federal government spent approximately $85 billion.
That figure includes the cost of drugs such as insulin and blood sugar controls, hospitalizations, surgeries and amputations, and the disease’s estimated indirect costs associated with time off work, disability claims, and forced early retirement.
The $218 billion, equal to about 10 percent of all U.S. spending on healthcare, compares to an estimated $448.5 billion spent annually on cardiovascular diseases such as heart attack and stroke.
The study was conducted by Lewin Group consultants.